Kyntra Bio, Inc. (KYNB)
NASDAQ: KYNB · Real-Time Price · USD
6.40
-0.19 (-2.88%)
Mar 30, 2026, 12:54 PM EDT - Market open
Kyntra Bio Revenue
In the year 2025, Kyntra Bio had annual revenue of $6.44M, down -78.26%. Kyntra Bio had revenue of $1.28M in the quarter ending December 31, 2025.
Revenue (ttm)
$6.44M
Revenue Growth
-78.26%
P/S Ratio
4.14
Revenue / Employee
$189,412
Employees
34
Market Cap
25.90M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 6.44M | -23.18M | -78.26% |
| Dec 31, 2024 | 29.62M | -17.18M | -36.71% |
| Dec 31, 2023 | 46.80M | -93.93M | -66.74% |
| Dec 31, 2022 | 140.73M | -94.58M | -40.19% |
| Dec 31, 2021 | 235.31M | 58.99M | 33.46% |
| Dec 31, 2020 | 176.32M | -80.26M | -31.28% |
| Dec 31, 2019 | 256.58M | 43.62M | 20.48% |
| Dec 31, 2018 | 212.96M | 81.96M | 62.57% |
| Dec 31, 2017 | 131.00M | -52.19M | -28.49% |
| Dec 31, 2016 | 183.19M | 2.36M | 1.31% |
| Dec 31, 2015 | 180.83M | 43.23M | 31.41% |
| Dec 31, 2014 | 137.60M | 35.43M | 34.68% |
| Dec 31, 2013 | 102.17M | 36.24M | 54.96% |
| Dec 31, 2012 | 65.93M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Dyadic International | 3.09M |
| Longeveron | 1.20M |
| IGC Pharma | 1.11M |
| ABVC BioPharma | 797.92K |
| Exicure | 500.00K |
| Serina Therapeutics | 130.00K |
KYNB News
- 13 days ago - Kyntra Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 21 days ago - Kyntra Bio to Report Fourth Quarter and Full Year 2025 Financial Results - GlobeNewsWire
- 4 weeks ago - What's Going On With Kyntra Bio Stock Tuesday? - Benzinga
- 4 weeks ago - Kyntra Bio Announces Positive Data from the Investigator-Sponsored Phase 1b/2 Study of FG-3246 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer to Be Presented at ASCO GU 2026 - GlobeNewsWire
- 5 weeks ago - Kyntra Bio to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - FibroGen Rebrands as Kyntra Bio to Reflect a New Era of Focus and Momentum - GlobeNewsWire
- 5 months ago - FibroGen to Report Third Quarter 2025 Financial Results - GlobeNewsWire
- 6 months ago - FibroGen Initiates Phase 2 Monotherapy Trial of FG-3246, a First-in-Class CD46 Targeting ADC, in Metastatic Castration-Resistant Prostate Cancer - GlobeNewsWire